Timely clinical updates and thought leadership on new drug and indication approvals, discontinuation and withdrawals, new dosages or formulations of existing products and generics introduced to the market. For questions regarding new updates, please email clinical@myMatrixx.com.
News and Updates
FDA Approves New Naloxone Products
May 02, 2024
Get the latest updates about newly, FDA-approved Rezenopy (naloxone hydrochloride) and naloxone nasal spray, 4mg/0.1mL, a generic to the OTC version of Narcan.
Learn more
Q1 2024 New Drug Report (January - March)
April 17, 2024
Read our new Q1 2024 (January through March) pipeline report that features new drug approvals, new generics, withdrawals and discontinuations of certain products, as well as near-term pipeline products and patent expirations.
Learn more
ODG Formulary Changes Planned for March 29
March 26, 2024
Effective March 29, ODG is updating Appendix A (its drug formulary). The planned changes will affect opioids, non-steroidal anti-inflammatory drugs (NSAIDs) and sedative hypnotics.
Learn more
FDA Approves Wegovy for Prevention of Major Cardiovascular Disease in Obese or Overweight Adults
March 13, 2024
On Friday, March 8, 2024, the FDA approved Wegovy (semaglutide) for a new indication--reduction of risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease who are obese or overweight. Wegovy should be used along with increased physical activity and a reduced calorie diet.
Learn more